Virtus LifeSci Biotech Clinical Trials ETF News
Battered pharma stocks bounce back, could boost retirement portfolios
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
Five ‘Industries of the Future’ Investors Can’t Ignore
Robotics will be one of the dominant industries of the not too distant future and investors better take notice, said Alec Ross, author of The Industries of the Future.
Two ETF plays for when biotech stocks bounce back.
The lack of major drug launches last year, along with disappointing quarterly results, dragged down biotech stocks last year. The downtrend has continued into 2016.
Two ETFs to Play a Bounce Back in Biotech
The lack of major drug launches last year, along with disappointing quarterly results, dragged down biotech stocks last year but they could soon be headed higher.
Citigroup: Financial Winners and Losers
Citigroup was among the best performers of the financial sector Friday, rising after reports the bank has restarted efforts to unload its Japanese call center.
Morgan Stanley Stock Leads Gains As Banks Boost Dividends After Fed Stress Tests
Morgan Stanley, Wells Fargo, Bank of America and Goldman Sachs will lift their quarterly dividend, while JPMorgan will hold its steady following last week's Fed stress tests.
Nike Stock Slides As As Margin Pressures, China Worries Offset Q4 Earnings Beat
"We think we're well positioned for growth in fiscal year 2023 ... having said that, we did take a cautious approach to Greater China," said CFO Matthew Friend.
Stocks Higher, Bank Dividends, Nike, Playtika And Occidental- Five Things To Know
Stock futures higher on global growth bets; Morgan Stanley leads bank gains after dividend boost; Nike slides as margin pressures offset Q4 earnings beat; Playtika shares surge on report of Joffre Capital interest and Occidental shares jump as Buffett adds more to stake
Walgreens Stock Slides As Group Scraps Plan to Sell UK-based Boots
"As a result of market instability ... no third party has been able to make an offer that adequately reflects the high potential value of Boots," Walgreens said.